Drugs / TAK-715
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00760864 | Aug 2004 → Sep 2005 | rheumatoid arthritis | Takeda | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-715 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00760864 ↗ |
| Action | Inhibit | “TAK-715 is a p38 mitogen-activated protein kinase inhibitor” NCT00760864 ↗1“MAP kinase p38 alpha inhibitor” CHEMBL363648 ↗ |
| Modality | Small molecule | — CHEMBL363648 ↗ |
| Route | Oral | “TAK-715 25 mg, tablets, orally, twice daily” NCT00760864 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL363648 ↗ |